TO THE NATIONAL STOCK MARKET COMMISSION

Madrid, 7th of September, 2017

In compliance with the provisions of article 228 of the Securities Market Law and with Article 17 of the EU Regulation No. 596/2014 of European Parliament and Council, of the 16th of April, on market abuse, and further to the significant event number 218432 dated 10th of February of 2015, Laboratorios Farmacéuticos ROVI, S.A. ("**ROVI**" or the "**Company**") informs that the national marketing authorization phase of the registration process for a low molecular weight heparin (biosimilar of enoxaparin) has been approved in Germany by local authorities and its marketing has been initiated.

Germany is the first European country where ROVI launches its biosimilar of enoxaparin, one of the top enoxaparin countries in Europe (in terms of volume and value).

ROVI will continue to regularly update about the relevant milestones in this national stage of the marketing authorization process according to the registration of the medicinal product progress.

Thanking you in advance for your attention, I remain yours sincerely,

D. Juan López-Belmonte Encina
Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A